Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Liabilities: 2017-2024

Historic Other Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $157.0 million.

  • Arcus Biosciences' Other Non-Current Liabilities rose 11.76% to $152.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 11.76%. This contributed to the annual value of $157.0 million for FY2024, which is 10.56% up from last year.
  • Latest data reveals that Arcus Biosciences reported Other Non-Current Liabilities of $157.0 million as of FY2024, which was up 10.56% from $142.0 million recorded in FY2023.
  • Arcus Biosciences' Other Non-Current Liabilities' 5-year high stood at $157.0 million during FY2024, with a 5-year trough of $543,000 in FY2020.
  • Over the past 3 years, Arcus Biosciences' median Other Non-Current Liabilities value was $142.0 million (recorded in 2023), while the average stood at $146.3 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 32.63% in 2020, then skyrocketed by 22,367.77% in 2021.
  • Yearly analysis of 5 years shows Arcus Biosciences' Other Non-Current Liabilities stood at $543,000 in 2020, then surged by 22,367.77% to $122.0 million in 2021, then increased by 14.75% to $140.0 million in 2022, then grew by 1.43% to $142.0 million in 2023, then grew by 10.56% to $157.0 million in 2024.